Cuu Long Pharmaceutical JSC
VN:DCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (11.3), the stock would be worth ₫-5 339.59 (114% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -77.8 | ₫36 900 |
0%
|
| Industry Average | 11.3 | ₫-5 339.59 |
-114%
|
| Country Average | 11.1 | ₫-5 286.38 |
-114%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| VN |
C
|
Cuu Long Pharmaceutical JSC
VN:DCL
|
2.7T VND | -77.8 | 138.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 140.4 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 29.1 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 34.8 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 19 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 24.8 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 42.2 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 21.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 11.6 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7 |
| Median | 11.1 |
| 70th Percentile | 19.2 |
| Max | 3 399.4 |
Other Multiples
Cuu Long Pharmaceutical JSC
Glance View
Cuu Long Pharmaceutical JSC engages in the manufacture, sale, import, and export of pharmaceutical, capsules, and medical instruments. The company is headquartered in Vinh Long, Vinh Long and currently employs 934 full-time employees. The company went IPO on 2008-09-17. The firm manufactures, markets and distributes pharmaceutical drugs and capsules, as well as medical equipment and supplies. The company is also involved in the manufacture and trading of functional food, cosmetic products, chemicals and other materials for pharmaceutical production. Other activities include the manufacture of specialized packagings for drugs and medical products, as well as the cultivation of traditional herbs.
